Results 371 to 380 of about 857,410 (384)
Some of the next articles are maybe not open access.
Tyrosine kinase inhibitors—ZD1839 (Iressa)
Current Opinion in Oncology, 2001Several epithelial tumors display epidermal growth factor receptor (EGFR) overexpression (with or without EGFR gene amplification) that is often associated with increased production of EGFR ligands. This permits the activation of endogenous tumor EGFR via autocrine mechanisms, resulting in cellular proliferation and tumor growth.
David H. Johnson, Carlos L. Arteaga
openaire +3 more sources
Small molecule tyrosine kinase inhibitors in glioblastoma
Archives of pharmacal research, 2020Gayoung Kim, Y. Ko
semanticscholar +1 more source
Are Tyrosine Kinase Inhibitors the Better Serotonin Inhibitors?
American Journal of Respiratory and Critical Care Medicine, 2013Ralph T. Schermuly, Djuro Kosanovic
openaire +3 more sources
Tyrosine kinase inhibitors in chronic myeloid leukaemia: which, when, for whom?
Nature Reviews Clinical Oncology, 2017G. Rosti +3 more
semanticscholar +1 more source
Long-Term Side Effects of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia
Current Hematologic Malignancy Reports, 2016Lauren E. Caldemeyer +3 more
semanticscholar +1 more source
Hepatotoxicity of tyrosine kinase inhibitors
Toxicology Letters, 2015F. Paech +2 more
openaire +2 more sources
Drug–drug interactions in patients receiving tyrosine kinase inhibitors
Journal of Oncology Pharmacy Practice, 2018Kristine L Keller +3 more
semanticscholar +1 more source
Mechanisms of resistance to third-generation EGFR tyrosine kinase inhibitors
Frontiers in Medicine, 2016Shuhang Wang +3 more
semanticscholar +1 more source
Tyrosine Kinase Inhibitors and Vascular Toxicity: Impetus for a Classification System?
Current Oncology Reports, 2016J. Herrmann
semanticscholar +1 more source